This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Bicalutamide
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-PERMANENT HIGH
For a 20yo male with intact HPG, this would cause systemic feminization (breast tissue, libido loss, sexual dysfunction, ED) at hair-loss-effective dose — wrong tool entirely. Even for severe MPB cases, topical 5% bicalutamide is occasionally compounded but data is sparse. The legitimate use cases are prostate cancer + transgender feminization. Hepatotoxicity is the dominant safety signal (hepatocellular damage in 1-3% of cancer-dose users, occasional fatal cases) — even at low dose. SKIP-PERMANENT for the male MPB use case; OPTIONAL for the indicated populations (which are out of scope).
▸ Verdict change log
- 2026-06-05 — Initial verdict SKIP-PERMANENT. (stub)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.